Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data.

Wilcox MA, Savitz AJ, Addington AM, Gray GS, Guinan EC, Jackson JW, Lehner T, Normand SL, Ranu H, Senthil G, Spertus J, Valeri L, Ross JS.

NPJ Schizophr. 2018 Jun 27;4(1):14. doi: 10.1038/s41537-018-0055-7. Review.

2.

Antibody-based therapeutics: focus on prostate cancer.

Ross JS, Gray KE, Webb IJ, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Millowsky MI, Bander NH.

Cancer Metastasis Rev. 2005 Dec;24(4):521-37. Review.

PMID:
16408160
3.

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV.

Clin Cancer Res. 2003 Dec 15;9(17):6357-62.

4.

Targeted therapy for cancer: the HER-2/neu and Herceptin story.

Ross JS, Gray GS.

Clin Leadersh Manag Rev. 2003 Nov-Dec;17(6):333-40. Review.

PMID:
14692077
5.

Anticancer antibodies.

Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M.

Am J Clin Pathol. 2003 Apr;119(4):472-85. Review.

PMID:
12710120
6.

Antibody-based therapeutics in oncology.

Ross J, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A, Rolfe M.

Expert Rev Anticancer Ther. 2003 Feb;3(1):107-21. Review.

PMID:
12597355
7.

Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates.

Kirk AD, Tadaki DK, Celniker A, Batty DS, Berning JD, Colonna JO, Cruzata F, Elster EA, Gray GS, Kampen RL, Patterson NB, Szklut P, Swanson J, Xu H, Harlan DM.

Transplantation. 2001 Aug 15;72(3):377-84.

PMID:
11502964
8.
9.

Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.

Sturmhoefel K, Lee K, Gray GS, Thomas J, Zollner R, O'Toole M, Swiniarski H, Dorner A, Wolf SF.

Cancer Res. 1999 Oct 1;59(19):4964-72.

10.

Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders.

Ling V, Wu PW, Finnerty HF, Sharpe AH, Gray GS, Collins M.

Genomics. 1999 Sep 15;60(3):341-55.

PMID:
10493833
11.

Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein.

Swiniarski H, Sturmhoefel K, Lee K, Gray GS, Thomas JL, Wolf SF, Dorner AJ, O'Toole M.

Clin Immunol. 1999 Sep;92(3):235-45.

PMID:
10479528
12.

Induction, maintenance, and reversal of streptozotocin-induced insulin-dependent diabetes mellitus in the juvenile cynomolgus monkey (Macaca fascilularis).

Theriault BR, Thistlethwaite JR Jr, Levisetti MG, Wardrip CL, Szot G, Bruce DS, Rilo H, Li X, Gray GS, Bluestone JA, Padrid PA.

Transplantation. 1999 Aug 15;68(3):331-7.

PMID:
10459535
13.

B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.

Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K, Lee K, Wolf S, Gajewski TF, Fitch FW.

J Immunol. 1998 Nov 15;161(10):5268-75.

14.
15.

Embryonic stem cells and embryoid bodies express lymphocyte costimulatory molecules.

Ling V, Munroe RC, Murphy EA, Gray GS.

Exp Cell Res. 1998 May 25;241(1):55-65.

PMID:
9633513
16.

CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction.

Blair PJ, Riley JL, Levine BL, Lee KP, Craighead N, Francomano T, Perfetto SJ, Gray GS, Carreno BM, June CH.

J Immunol. 1998 Jan 1;160(1):12-5.

17.

Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation.

Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, Gray GS, Bruce DS, Thistlethwaite JR Jr, Bluestone JA.

J Immunol. 1997 Dec 1;159(11):5187-91.

PMID:
9548454
18.

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.

Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ.

Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8789-94.

19.

The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.

Rennert P, Furlong K, Jellis C, Greenfield E, Freeman GJ, Ueda Y, Levine B, June CH, Gray GS.

Int Immunol. 1997 Jun;9(6):805-13.

PMID:
9199963
20.

The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.

Boyer MW, Vallera DA, Taylor PA, Gray GS, Katsanis E, Gorden K, Orchard PJ, Blazar BR.

Blood. 1997 May 1;89(9):3477-85.

PMID:
9129056
21.

Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig.

Saha B, Jaklic B, Harlan DM, Gray GS, June CH, Abe R.

J Immunol. 1996 Nov 1;157(9):3869-75.

PMID:
8892617
22.

Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.

Blazar BR, Sharpe AH, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Korngold R, Vallera DA.

J Immunol. 1996 Oct 15;157(8):3250-9.

PMID:
8871619
23.

Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool.

Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM.

Blood. 1996 Jun 1;87(11):4887-93.

PMID:
8639863
24.

A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB.

Zhao J, Freeman GJ, Gray GS, Nadler LM, Glimcher LH.

J Exp Med. 1996 Mar 1;183(3):777-89.

25.

Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis.

Perrin PJ, Scott D, Davis TA, Gray GS, Doggett MJ, Abe R, June CH, Racke MK.

J Neuroimmunol. 1996 Mar;65(1):31-9.

PMID:
8642061
26.

Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies.

Lenschow DJ, Zeng Y, Hathcock KS, Zuckerman LA, Freeman G, Thistlethwaite JR, Gray GS, Hodes RJ, Bluestone JA.

Transplantation. 1995 Nov 27;60(10):1171-8.

PMID:
7482727
27.

Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.

Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ.

J Clin Invest. 1995 Nov;96(5):2195-203.

28.

Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules.

Hakim FT, Cepeda R, Gray GS, June CH, Abe R.

J Immunol. 1995 Aug 15;155(4):1757-66.

PMID:
7636232
29.

Very-low-dose streptozotocin induces diabetes in insulin promoter-mB7-1 transgenic mice.

Harlan DM, Barnett MA, Abe R, Pechhold K, Patterson NB, Gray GS, June CH.

Diabetes. 1995 Jul;44(7):816-23.

PMID:
7540575
30.

B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, Gray GS, Gribben JG, Nadler LM.

Immunity. 1995 May;2(5):523-32.

32.

T cell costimulation through the CD28 receptor.

Green JM, Noel PJ, Sperling AI, Walunas TL, Lenschow DJ, Stack R, Gray GS, Bluestone JA, Thompson CB.

Proc Assoc Am Physicians. 1995 Apr;107(1):41-6. No abstract available.

PMID:
8630743
33.

B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.

Katsanis E, Xu Z, Bausero MA, Dancisak BB, Gorden KB, Davis G, Gray GS, Orchard PJ, Blazar BR.

Cancer Gene Ther. 1995 Mar;2(1):39-46.

PMID:
7542553
34.

Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis.

Perrin PJ, Scott D, Quigley L, Albert PS, Feder O, Gray GS, Abe R, June CH, Racke MK.

J Immunol. 1995 Feb 1;154(3):1481-90.

PMID:
7529805
35.

CTLA4 mediates antigen-specific apoptosis of human T cells.

Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA Jr, Ke X, Gray GS, et al.

Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):811-5.

36.

Genomic organization of the gene coding for the costimulatory human B-lymphocyte antigen B7-2 (CD86).

Jellis CL, Wang SS, Rennert P, Borriello F, Sharpe AH, Green NR, Gray GS.

Immunogenetics. 1995;42(2):85-9.

PMID:
7541777
37.
38.

CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy.

Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG, Nadler LM.

J Exp Med. 1994 Nov 1;180(5):1665-73.

39.

Absence of B7-dependent responses in CD28-deficient mice.

Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB.

Immunity. 1994 Sep;1(6):501-8.

PMID:
7534617
40.

IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2.

Stack RM, Lenschow DJ, Gray GS, Bluestone JA, Fitch FW.

J Immunol. 1994 Jun 15;152(12):5723-33.

PMID:
7515912
41.

Costimulator dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice.

McKnight AJ, Perez VL, Shea CM, Gray GS, Abbas AK.

J Immunol. 1994 Jun 1;152(11):5220-5.

PMID:
7514632
42.

Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness.

Harlan DM, Hengartner H, Huang ML, Kang YH, Abe R, Moreadith RW, Pircher H, Gray GS, Ohashi PS, Freeman GJ, et al.

Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3137-41.

43.

Defining critical residues in the epitope for a HIV-neutralizing monoclonal antibody using phage display and peptide array technologies.

Jellis CL, Cradick TJ, Rennert P, Salinas P, Boyd J, Amirault T, Gray GS.

Gene. 1993 Dec 27;137(1):63-8.

PMID:
7506691
44.

Expression and functional significance of an additional ligand for CTLA-4.

Lenschow DJ, Su GH, Zuckerman LA, Nabavi N, Jellis CL, Gray GS, Miller J, Bluestone JA.

Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11054-8.

45.

Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA Jr, Lombard LA, Gray GS, Nadler LM.

Science. 1993 Nov 5;262(5135):909-11.

PMID:
7694363
46.

Characterization of CTLA-4 structure and expression on human T cells.

Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ, Lombard DB, Freeman GJ, Nadler LM, Gray GS, et al.

J Immunol. 1993 Oct 1;151(7):3489-99.

PMID:
8397258
47.

CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.

Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC, Hafler DA, Dorf ME, Gray GS, Reiser H, et al.

J Immunol. 1992 Dec 15;149(12):3795-801.

PMID:
1281186
48.

Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.

Freeman GJ, Gray GS, Gimmi CD, Lombard DB, Zhou LJ, White M, Fingeroth JD, Gribben JG, Nadler LM.

J Exp Med. 1991 Sep 1;174(3):625-31.

49.
50.

Expression and purification of active recombinant platelet factor 4 from a cleavable fusion protein.

Myers JA, Gray GS, Peters DJ, Grimaila RJ, Hunt AJ, Maione TE, Mueller WT.

Protein Expr Purif. 1991 Apr-Jun;2(2-3):136-43.

PMID:
1821782

Supplemental Content

Support Center